New drug JSB462 tested for advanced prostate cancer in japanese patients
NCT ID NCT07174063
First seen Jun 27, 2026 · Last updated Jul 09, 2026 · Updated 5 times
Summary
This early-stage study tests a new drug called JSB462 (Luxdegalutamide) in 15 Japanese men whose prostate cancer has spread to other parts of the body. The main goal is to check the drug's safety and how the body processes it. Participants take the drug once daily with food.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- JSB462 (Luxdegalutamide)
- What this could lead to
- If safe and effective, this drug could offer a new treatment option for Japanese men with advanced prostate cancer that has spread.
- What could go wrong
- This is a very early Phase 1 trial with only 15 participants, so it's too soon to know if the drug works. Side effects are unknown and could be serious.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE CANCER (MCRPC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Novartis Investigative Site
Nagoya, Aichi-ken, 4668560, Japan
-
Novartis Investigative Site
Kobe, Hyōgo, 650-0017, Japan
-
Novartis Investigative Site
Bunkyo Ku, Tokyo, 1138677, Japan
-
Novartis Investigative Site
Koto Ku, Tokyo, 1358550, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.